Published in J Biol Chem on March 22, 2010
Cross talk among TGF-β signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb Perspect Biol (2011) 1.60
LTBPs, more than just an escort service. J Cell Biochem (2012) 1.37
Thrombospondin1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms. Matrix Biol (2012) 1.23
Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest (2011) 1.11
Unchaining the beast; insights from structural and evolutionary studies on TGFβ secretion, sequestration, and activation. Cytokine Growth Factor Rev (2013) 1.08
Choreographing metastasis to the tune of LTBP. J Mammary Gland Biol Neoplasia (2011) 0.90
Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther (2012) 0.86
Development of novel activin-targeted therapeutics. Mol Ther (2014) 0.85
Pregnancy-specific glycoprotein 1 (PSG1) activates TGF-β and prevents dextran sodium sulfate (DSS)-induced colitis in mice. Mucosal Immunol (2013) 0.83
The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy. PLoS One (2015) 0.80
Matricellular protein thrombospondins: influence on ocular angiogenesis, wound healing and immuneregulation. Curr Eye Res (2014) 0.79
LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis. Springerplus (2014) 0.78
Inhibition of TGFβ cell signaling for limbal explant culture in serumless, defined xeno-free conditions. Exp Eye Res (2015) 0.78
Extracellular Regulation of Bone Morphogenetic Protein Activity by the Microfibril Component Fibrillin-1. J Biol Chem (2016) 0.77
Structural Basis for the Effective Myostatin Inhibition of the Mouse Myostatin Prodomain-Derived Minimum Peptide. ACS Med Chem Lett (2016) 0.75
Maltose binding protein-fusion enhances the bioactivity of truncated forms of pig myostatin propeptide produced in E. coli. PLoS One (2017) 0.75
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature (1991) 11.44
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet (2005) 9.62
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A (2001) 6.38
Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell (1992) 4.68
TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med (2009) 4.58
Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem (1988) 3.98
Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem (1988) 3.91
Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A (1983) 3.52
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem (2002) 3.01
Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem (2004) 2.97
Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol (2007) 2.94
Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol (2004) 2.90
Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta (2008) 2.72
Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem (1989) 2.44
The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem (1999) 2.43
Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor beta to the mature polypeptide. Mol Cell Biol (1988) 2.24
Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol (1994) 2.15
Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev (2002) 2.13
Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet (2000) 2.02
Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem (1995) 1.99
The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem (2005) 1.91
GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors (2001) 1.88
Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem (2008) 1.80
Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol (2002) 1.80
Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem (1996) 1.79
ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet (2008) 1.78
Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet (2005) 1.69
The pro domain of pre-pro-transforming growth factor beta 1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry (1990) 1.63
Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet (2000) 1.63
Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol (1995) 1.58
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol (2005) 1.54
Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J (1996) 1.50
Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res (1998) 1.48
Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J Biol Chem (1996) 1.40
Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. Proc Natl Acad Sci U S A (2008) 1.40
Molecular interactions that confer latency to transforming growth factor-beta. J Biol Chem (2004) 1.38
Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability. J Cell Biol (2002) 1.37
The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem (2004) 1.29
Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet (2006) 1.27
The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem (1995) 1.25
Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem (2008) 1.23
A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7. J Mol Biol (2008) 1.21
Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J Biol Chem (2002) 1.13
Bone defects in latent TGF-beta binding protein (Ltbp)-3 null mice; a role for Ltbp in TGF-beta presentation. J Endocrinol (2002) 1.10
Mutational screening of the coding region of growth differentiation factor 9 gene in Indian women with ovarian failure. Menopause (2005) 1.10
Disruption of the latent transforming growth factor-beta binding protein-1 gene causes alteration in facial structure and influences TGF-beta bioavailability. Biochim Biophys Acta (2007) 1.01
Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1-latency-associated peptide. Biochem J (1996) 0.99
Amino acid requirements for formation of the TGF-beta-latent TGF-beta binding protein complexes. J Mol Biol (2005) 0.98
Osteopetrosis-like phenotype in latent TGF-beta binding protein 3 deficient mice. Bone (2005) 0.98
Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1. J Biol Chem (2001) 0.98
Analyses of GDF9 mutation in 100 Chinese women with premature ovarian failure. Fertil Steril (2007) 0.94
Identification and analysis of discrete functional domains in the pro region of pre-pro-transforming growth factor beta 1. J Cell Biol (1991) 0.93
A novel mutation of TGF beta1 in a Chinese family with Camurati-Engelmann disease. Bone (2007) 0.88
A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J Biol Chem (2009) 0.87
The latent-TGFbeta-binding-protein-1 (LTBP-1) is expressed in the organizer and regulates nodal and activin signaling. Dev Biol (2002) 0.84
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet (2009) 3.33
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol (2005) 2.52
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl (2002) 1.76
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev (2012) 1.64
Hormonal changes in the menopause transition. Recent Prog Horm Res (2002) 1.62
Differences in allergic sensitization by self-reported race and genetic ancestry. J Allergy Clin Immunol (2008) 1.47
The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause. Menopause (2005) 1.47
Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab (2007) 1.44
Ovarian status in healthy postmenopausal women: follow-up 12 months after transvaginal ultrasound. Menopause (2009) 1.42
Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab (2005) 1.40
Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano (2011) 1.38
Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci U S A (2003) 1.35
Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab (2004) 1.29
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res (2010) 1.21
Expression of nodal signalling components in cycling human endometrium and in endometrial cancer. Reprod Biol Endocrinol (2009) 1.18
A complex containing alpha6beta1-integrin and phosphorylated focal adhesion kinase between Sertoli cells and elongated spermatids during spermatid release from the seminiferous epithelium. J Endocrinol (2006) 1.16
Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab (2002) 1.15
Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause (2008) 1.14
Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J Biol Chem (2006) 1.13
Elevated expression of activins promotes muscle wasting and cachexia. FASEB J (2013) 1.13
The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol (2013) 1.12
Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause (2009) 1.10
Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. J Cell Biol (2012) 1.10
Post-translational modifications and protein-specific isoforms in endometriosis revealed by 2D DIGE. J Proteome Res (2010) 1.05
Natural variation in four human collagen genes across an ethnically diverse population. Genomics (2008) 1.03
Proteomic characterization of midproliferative and midsecretory human endometrium. J Proteome Res (2009) 1.01
Growth differentiation factor 9 is a germ cell regulator of Sertoli cell function. Endocrinology (2008) 1.01
Green technologies for room temperature nucleic acid storage. Curr Issues Mol Biol (2009) 1.01
Generation of a specific activin antagonist by modification of the activin A propeptide. Endocrinology (2011) 1.00
Activation of latent human GDF9 by a single residue change (Gly 391 Arg) in the mature domain. Endocrinology (2012) 0.99
Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases: potential interactions during decidualization and trophoblast invasion. Endocrinology (2005) 0.98
Hormonal regulation of sertoli cell micro-RNAs at spermiation. Endocrinology (2011) 0.95
The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax (2012) 0.94
Proteomics of the human endometrium and uterine fluid: a pathway to biomarker discovery. Fertil Steril (2012) 0.94
14-3-3:Shc scaffolds integrate phosphoserine and phosphotyrosine signaling to regulate phosphatidylinositol 3-kinase activation and cell survival. J Biol Chem (2009) 0.92
A distinct cohort of the TGFbeta superfamily members expressed in human endometrium regulate decidualization. Hum Reprod (2008) 0.92
New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol (2011) 0.92
Growth differentiation factor 9:bone morphogenetic protein 15 (GDF9:BMP15) synergism and protein heterodimerization. Proc Natl Acad Sci U S A (2013) 0.89
Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities. Endocrinology (2006) 0.89
Suppression of inhibin A biological activity by alterations in the binding site for betaglycan. J Biol Chem (2008) 0.89
A maternally inherited chromosome 18q22.1 deletion in a male with late-presenting diaphragmatic hernia and microphthalmia-evaluation of DSEL as a candidate gene for the diaphragmatic defect. Am J Med Genet A (2010) 0.88
Gonadotropins regulate rat testicular tight junctions in vivo. Endocrinology (2010) 0.88
Variability of the location of the tibial tubercle affects the rotational alignment of the tibial component in kinematically aligned total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc (2012) 0.88
The relative roles of follicle-stimulating hormone and luteinizing hormone in maintaining spermatogonial maturation and spermiation in normal men. J Clin Endocrinol Metab (2006) 0.87
A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands. J Biol Chem (2009) 0.87
Microbial biotin protein ligases aid in understanding holocarboxylase synthetase deficiency. Biochim Biophys Acta (2008) 0.87
Variability in sperm suppression during testosterone administration to adult monkeys is related to follicle stimulating hormone suppression and not to intratesticular androgens. J Clin Endocrinol Metab (2002) 0.85
Inhibin A and B in vitro bioactivities are modified by their degree of glycosylation and their affinities to betaglycan. Endocrinology (2007) 0.84
Promoting extracellular matrix remodeling via ascorbic acid enhances the survival of primary ovarian follicles encapsulated in alginate hydrogels. Biotechnol Bioeng (2014) 0.84
Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab (2004) 0.84
Tumour necrosis factor-α stimulates human neutrophils to release preformed activin A. Immunol Cell Biol (2011) 0.83
Retinoic acid promotes Sertoli cell differentiation and antagonises activin-induced proliferation. Mol Cell Endocrinol (2013) 0.83
Supplemented αMEM/F12-based medium enables the survival and growth of primary ovarian follicles encapsulated in alginate hydrogels. Biotechnol Bioeng (2013) 0.82
An optimized procedure for the capture, fractionation and proteomic analysis of proteins using hydrogel nanoparticles. Proteomics (2010) 0.82
Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12-month-old infant. J Clin Endocrinol Metab (2002) 0.82
Inhibin B is a more potent suppressor of rat follicle-stimulating hormone release than inhibin a in vitro and in vivo. Endocrinology (2009) 0.82
Species differences in the expression and activity of bone morphogenetic protein 15. Endocrinology (2013) 0.80
Inhibin α-subunit N terminus interacts with activin type IB receptor to disrupt activin signaling. J Biol Chem (2012) 0.80
Activin signaling regulates Sertoli cell differentiation and function. Endocrinology (2012) 0.80
Proteomic analysis of the intestinal adaptation response reveals altered expression of fatty acid binding proteins following massive small bowel resection. J Proteome Res (2010) 0.79
Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res (2013) 0.79
Rodent adrenocortical cells display high affinity binding sites and proteins for inhibin A, and express components required for autocrine signalling by activins and bone morphogenetic proteins. J Endocrinol (2006) 0.79
Interleukin 11 and activin A synergise to regulate progesterone-induced but not cAMP-induced decidualization. J Reprod Immunol (2010) 0.79
Feedback regulation by inhibins A and B of the pituitary secretion of follicle-stimulating hormone. Vitam Horm (2011) 0.79
Mutational analysis of betaglycan/TGF-betaRIII in premature ovarian failure. Fertil Steril (2006) 0.79
Extracardiac coronary arterial anastomoses. Clin Anat (2010) 0.78
5alpha-reductase isoenzymes 1 and 2 in the rat testis during postnatal development. Biol Reprod (2002) 0.78
Can a simple urinalysis predict the causative agent and the antibiotic sensitivities? Pediatr Emerg Care (2014) 0.77
Lentiviral transduction of rat Sertoli cells as a means to modify gene expression. Spermatogenesis (2012) 0.77
Extra-ovarian expression and activity of growth differentiation factor 9. J Endocrinol (2009) 0.77
Aberrant GDF9 expression and activation are associated with common human ovarian disorders. J Clin Endocrinol Metab (2014) 0.77
Functional analysis of the human inhibin alpha subunit variant A257T and its potential role in premature ovarian failure. Hum Reprod (2007) 0.77
Activin-β(c) reduces reproductive tumour progression and abolishes cancer-associated cachexia in inhibin-deficient mice. J Pathol (2013) 0.77
The synthesis and secretion of inhibins. Vitam Horm (2011) 0.76